---
document_datetime: 2023-09-21 20:43:12
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/telmisartan-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: telmisartan-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.5267325
conversion_datetime: 2025-12-25 05:55:23.867901
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Telmisartan Teva Pharma

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0024            | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 08/10/2021                          |                                             | SmPC, Labelling and PL           |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| N/0023    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                           | 17/09/2021   |            | PL              |           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------|
| IA/0022   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                              | 12/01/2021   |            | Annex II and PL |           |
| IA/0021   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                               | 31/07/2019   | n/a        |                 |           |
| IB/0020   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                               | 19/06/2019   | 25/07/2019 | SmPC and PL     |           |
| IA/0019/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 03/05/2019   | n/a        |                 |           |
| IA/0017   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                         | 08/07/2016   | n/a        |                 | procedure |

<div style=\"page-break-after: always\"></div>

| IA/0016   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                           | 14/06/2016   | n/a        |                                  |                                                                                                                                                                                                                                                                                       |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0014    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                 | 28/04/2016   | 09/06/2016 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Telmisartan Teva Pharma in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IA/0015/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites                                       | 19/04/2016   | 09/06/2016 | Annex II and PL                  |                                                                                                                                                                                                                                                                                       |
| T/0012    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                     | 22/01/2015   | 10/02/2015 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                                       |
| A31/0006  | On 17 April 2013, further to the emergence of new evidence from the scientific literature on dual RAS blockade therapy and given the seriousness of the identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the Pharmacovigilance Risk Assessment Committee | 22/05/2014   | 04/09/2014 | SmPC and PL                      | For further information please refer to the Renin- angiotensin-system (RAS)-acting agents Article 31 referral - Assessment report.                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                    | risk of dual RAS blockade therapy through the combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers (ARBs) or aliskiren and to determine whether any regulatory measures should be taken on the marketing authorisations of the products involved in this procedure.                                                                                                                                     |            |            |                       |                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------|
| IB/0011            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                   | 30/04/2014 | 06/06/2014 | SmPC and PL           |                                   |
| PSUSA/2882/ 201304 | Periodic Safety Update EU Single assessment - hydrochlorothiazide / telmisartan, telmisartan                                                                                                                                                                                                                                                                                                                                                                   | 07/11/2013 | n/a        |                       | PRAC Recommendation - maintenance |
| IB/0008/G          | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference | 09/10/2013 | 06/06/2014 | SmPC, Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|             | - Implementation of change(s) for which NO additional data is required to be submitted by MAH                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        | product new the   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------|
| IA/0009     | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                 | 27/09/2013 | n/a        |                        |                   |
| IAIN/0007/G | This was an application for a group of variations. B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a manufacturer (replacement or addition)                                                                                                                              | 04/09/2013 | n/a        |                        | new               |
| IAIN/0005/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished | 05/06/2013 | 06/06/2014 | SmPC, Labelling and PL | product - Change  |

<div style=\"page-break-after: always\"></div>

|           | ampoules, etc.) in a pack - Change within range of the currently approved pack sizes - Changes (Safety/Efficacy) of Human and Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        | tablets, the C.I.z Veterinary   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------|
| IA/0004/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/03/2013 | n/a        |                        | manufacturing                   |
| IB/0003/G | This was an application for a group of variations. Update of section 4.4 of the SmPC to include a warning for diabetic patients when treated with insulin or oral antidiabetics and to include a warning on RAAS blockage in patients with uncontrolled blood pressure, and update to section 4.8 of the SmPC to include \"cough\", \"somnolence\" and \"interstitial lung disease\" as new ADR and consequential changes to section 4 of the Package Leaflet. These changes are implemented following approval of variation EMEA/H/C/000209/WS/0220 for Micardis. Update of sections 4.1, 4.2, 4.8 and 5.1 of the SmPC and consequently sections 1, 3 and 4 of the Package Leaflet to add indication of cardiovascular prevention in line with the indications registered for the reference product Micardis. This indication was | 26/07/2012 | 29/10/2012 | SmPC, Labelling and PL |                                 |

<div style=\"page-break-after: always\"></div>

|           | registered for the reference product Micardis via variation EMEA/H/C/000209/II/0073. In addition the MAH has aligned the Annexes with version 8 of the QRD template and updated the list of local representatives in the Package Leaflet for Austria, Estonia, Finland, Germany, Italy, Ireland, Norway and United Kingdom. Furthermore, minor amendments have been introduced in some languages to keep the Product Information in line with the originator product. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0001/G | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the currently approved batch size B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 09/07/2012 | n/a |

<div style=\"page-break-after: always\"></div>

|             | the specification parameters and/or limits of the immediate packaging of the AS - Other variation B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                 |            |            |                        | B.I.c.2.z - Change in   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------|
| IAIN/0002/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 16/05/2012 | 29/10/2012 | SmPC, Labelling and PL |                         |